HRT clinical evaluation guidance
Executive Summary
Sponsors of estrogen/progestin combination clinical trials should "identify the lowest effective dose" of estrogen and progestin to support an indication for moderate to severe vasomotor symptoms and vulvar and vaginal atrophy associated with menopause, FDA draft guidance says. The guidance, "Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms - Recommendations for Clinical Evaluation," notes that the hormone combination may be associated with an increased risk of breast cancer and cardiovascular events. The "lowest effective dose" recommendation comes although "specific relationships between dose, exposure, and the risk of adverse events may not be known." The draft guidance would replace 1995 recommendations that FDA withdrew following publication of WHI study results (1"The Pink Sheet" July 15, 2002, p. 11)...
You may also be interested in...
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Wyeth is sending letters to approximately 550,000 physicians as part of a Prempro risk management program to address risks associated with use of the hormone combination for cardiovascular disease and osteoporosis prevention
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.